Justin Kim
Stock Analyst at Oppenheimer
(1.30)
# 3,538
Out of 5,182 analysts
39
Total ratings
41.94%
Success rate
-4.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $16 → $15 | $5.30 | +183.02% | 3 | Mar 20, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $28.22 | +77.18% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $40.99 | -2.42% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $60.69 | +74.66% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $28.79 | +202.19% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $37.11 | -29.94% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $1.57 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $16.04 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $8.86 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $71.78 | -17.80% | 1 | Jul 18, 2022 |
Zura Bio
Mar 20, 2026
Maintains: Outperform
Price Target: $16 → $15
Current: $5.30
Upside: +183.02%
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $28.22
Upside: +77.18%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $40.99
Upside: -2.42%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $60.69
Upside: +74.66%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $28.79
Upside: +202.19%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $37.11
Upside: -29.94%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.57
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $16.04
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $8.86
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $71.78
Upside: -17.80%